How do I differentiate my VC thesis?

The ten dimensions differentiation can actually come from

Most decks differentiate on one, sometimes two. The ones that hold up in diligence usually combine three, and can say why the combination is hard to copy.

• Stage. Where you enter, and whether the discipline to stay there survives a hot round in a company you love.
• Sector. What you know deeply enough that a founder learns something in the first meeting.
• Geography. Where you are physically present, and what that presence gets you that a visiting investor cannot get.
• Portfolio construction. Concentration, ownership, and reserves are strategy rather than administration, and a genuinely different construction is a genuine differentiator.
• Sourcing. Named, repeatable channels rather than a network. This is the differentiator allocators test hardest, and it has its own page in this library.
• Decision speed. A documented process that lets you commit faster than a committee, which matters at stages where speed decides allocation.
• Founder value-add. Specific, evidenced, and describable by founders rather than by you.
• Network. Not the size of it, but which specific people take your call and what that unlocks for a portfolio company.
• Strategy boundaries. What you will not do, which is the cheapest differentiator to state and the one most managers omit.
• Competitor mapping. Knowing precisely which funds you are compared against, which is itself a signal about how well you understand your market.

Why the usual language is not enough

Phrases like investing in overlooked founders, backing exceptional teams, or being founder-friendly fail for the same structural reason: every fund in the category says them, so the sentence carries no information. That is not a writing problem and rewriting it more vividly does not fix it.

The repair is always the same. Convert the claim into something falsifiable, then attach the evidence. Overlooked founders becomes a specific population, reached through a specific channel, with the last ten deals showing where they came from. Founder-friendly becomes three founders an allocator may call, including one whose company failed.

Cambridge Associates, describing its own venture practice, points at why this matters commercially rather than aesthetically: the wide dispersion of returns present in venture capital investing is what makes manager selection so demanding, so an allocator's whole job is telling apart funds whose decks say the same thing.

The thesis comparison table

Fill one row per claim you intend to make. Do it for your own fund and then, honestly, for the three funds you are most often compared against. The rows that survive are your thesis; the rest is category language.

• Stated claim. The sentence as you would say it in a meeting.
• Evidence. What makes it checkable: deals, dates, channels, named people, published facts.
• Comparable funds. Which funds an allocator would put beside you, named internally even if never named publicly.
• Crowded language. Whether those funds say the same sentence. If they do, the claim is not differentiation regardless of whether it is true.
• Actual whitespace. What remains once the shared claims are deleted, stated as what you do that they structurally cannot or will not.
• Remaining uncertainty. What you do not yet know about whether the edge holds, written plainly. This column is what makes the exercise honest, and allocators respond to it far better than managers expect.

How to find the whitespace, mechanically

Four steps, and none requires new information.

• List the funds you are compared against, by name, internally. If you cannot name five, that gap is the first thing to fix, because an allocator can.
• Write their thesis sentence as they would write it, from their own public materials.
• Delete every claim of yours that appears in two or more of theirs. What is left is your candidate differentiation, and it is usually much shorter than the original deck.
• Test each survivor against a founder question: would a founder choose you over them because of this, and could that founder explain why in one sentence? A differentiator a founder cannot articulate is a differentiator that does not affect deal outcomes.

What limited partners are testing

Five things, and none of them is whether the thesis is exciting.

• Is the boundary tight enough that off-thesis deals are identifiable without asking the manager?
• Does the differentiation survive one follow-up question, or does it dissolve into a general claim?
• Does the portfolio construction match the thesis, or does the arithmetic describe a different fund?
• Is the edge structural, meaning it comes from access, expertise, or position, rather than from effort every fund also expends?
• Would the funds you are compared against agree that you occupy different ground?

Where differentiation reads differently by market

The method is global. What counts as differentiated is local.

• In deep, crowded markets, sector and stage alone rarely differentiate, and the burden falls on sourcing and construction.
• In markets with fewer active funds, geography and presence can be genuine differentiation on their own, and the harder question becomes whether the opportunity set supports the fund size.
• For cross-border strategies, the differentiator is often the ability to operate in two markets at once, which is evidenced by the operating layer rather than by the thesis paragraph.
• Where public or development capital is a material part of the base, mandate alignment is not differentiation, since every applicant claims it. What differentiates is documented capability against the programme's own published requirements.

What a differentiated thesis does not prove

It does not prove you can execute it. Differentiation gets a fund taken seriously; sourcing evidence, portfolio arithmetic, and references are what carry it through diligence.

This page states no view on which theses are currently in favour, and deliberately publishes no list of crowded or uncrowded sectors, because that is a market observation with a short shelf life and none was verified.

This page is educational and general. It is not legal, tax, securities, or investment advice.